Siegel, David S <br/><br/>
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.  [electronic resource] 

 -  Blood  Oct 2012 
 - 2817-25 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2012-05-425934  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Drug Resistance, Neoplasm<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasm Staging<br/>Oligopeptides--therapeutic use<br/>Pilot Projects<br/>Prognosis<br/>Salvage Therapy<br/>Survival Rate